Results 211 to 220 of about 55,766 (252)

Ciprofloxacin- and levofloxacin-loaded nanoparticles efficiently suppressed fluoroquinolone resistance and biofilm formation in Acinetobacter baumannii. [PDF]

Sci Rep
Aboelenin AM, El-Mowafy M, Saleh NM, Shaaban MI, Barwa R.   +4 more
europepmc   +1 more source

Detection of Macrolide and/or Fluoroquinolone Resistance Genes in Mycoplasma genitalium Strains Isolated from Men in the Northwest Region of Croatia in 2018-2023. [PDF]

Genes (Basel)
Ljubin-Sternak S, Meštrović T, Marijan T, Anušić M, Šuto S, Vraneš J.   +5 more
europepmc   +1 more source

Molecular Mechanisms of Fluoroquinolone Resistance in Klebsiella [PDF]

Current Drug Target -Infectious Disorders, 2004
Klebsiella are well-recognized community and nosocomial pathogens responsible for septicemias, urinary tract infections, pneumonia, and soft tissue infections. The emergence of multi-drug resistant Klebsiella is becoming a global concern. Since fluoroquinolones are excellent antibiotics for clinical therapy of complicated infections, their consumptions
Yun-Liang, Yang, Tsai-Ling, Lauderdale, Hsiu-Jung, Lo   +2 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Fluoroquinolone Use and Fluoroquinolone Resistance: Is There an Association?

Clinical Infectious Diseases, 1994
In an assessment of potential risk factors for nosocomial infections caused by fluoroquinolone-resistant gram-negative organisms, 68 patients who developed a nosocomial infection caused by a fluoroquinolone-resistant gram-negative bacillus were compared with 191 patients who developed a nosocomial infection caused by a fluoroquinolone-susceptible gram ...
P, Richard, M H, Delangle, D, Merrien, S, Barillé, A, Reynaud, C, Minozzi, H, Richet   +6 more
openaire   +2 more sources

Fluoroquinolones, tuberculosis, and resistance

The Lancet Infectious Diseases, 2003
Although the fluoroquinolones are presently used to treat tuberculosis primarily in cases involving resistance or intolerance to first-line antituberculosis therapy, these drugs are potential first-line agents and are under study for this indication.
Amy Sarah, Ginsburg, Jacques H, Grosset, William R, Bishai   +2 more
openaire   +2 more sources

Fluoroquinolones: Action and Resistance

Current Topics in Medicinal Chemistry, 2003
Fluoroquinolones trap gyrase and topoisomerase IV on DNA as ternary complexes that block the movement of replication forks and transcription complexes. Studies with resistant mutants indicate that during complex formation quinolones bind to a surface alpha-helix of the GyrA and ParC proteins.
Karl, Drlica, Muhammad, Malik
openaire   +2 more sources

Occurrence of fluoroquinolones and fluoroquinolone-resistance genes in the aquatic environment

Science of The Total Environment, 2013
Fluoroquinolones (FQs) have been detected in aquatic environments in several countries. Long-term exposure to low levels of antimicrobial agents provides selective pressure, which might alter the sensitivity of bacteria to antimicrobial agents in the environment. Here, we examined FQ levels and the resistance of Escherichia coli (E.
Fumie, Adachi, Atsushi, Yamamoto, Koh-Ichi, Takakura, Ryuji, Kawahara   +3 more
openaire   +2 more sources

Bacterial Resistance to Fluoroquinolones

Clinical Infectious Diseases, 1988
Fluoroquinolones inhibit bacteria by interacting with the A subunit of DNA gyrase. Resistance to older agents such as nalidixic acid was due to mutations in the gyrA gene. Resistance to the new fluoroquinolones (e.g., norfloxacin, enoxacin, ofloxacin, pefloxacin, and ciprofloxacin) as a consequence of spontaneous single-step mutation occurs at a low ...
openaire   +2 more sources